INTELLECTUAL PROPERTY
Pantarhin’s pharmaceutical development strategy is supported by issued U.S. patents relating to defined therapeutic uses of hyaluronidase in cardiovascular disease.
The issued U.S. patents contain therapeutic-use claims directed to hyaluronidase and are not limited in their independent claims to the specific D016 recombinant enzyme sequence.
This intellectual-property position is distinct from the D016 technology itself and forms an additional layer supporting Pantarhin’s cardiovascular pharmaceutical development strategy.
Issued U.S. Patents ·Therapeutic-Use Claims ·Cardiovascular Development ·D016 Technology
Issued U.S. Patents
Pantarhin’s current issued U.S. patent portfolio includes therapeutic-use patents directed to defined cardiovascular applications of hyaluronidase.
Therapeutic field: Arterial hypertension
The patent includes claims directed to the use of hyaluronidase for the treatment of arterial hypertension. The independent claim is directed to hyaluronidase and is not limited to the specific D016 recombinant enzyme sequence.
Current status: Active
Adjusted expiration: July 20, 2033
Therapeutic field: Cardiac insufficiency
The patent includes claims directed to the use of hyaluronidase for the treatment of cardiac insufficiency. The independent claim is likewise directed to hyaluronidase and is not limited to the specific D016 recombinant enzyme sequence.
Current status: Active
Anticipated expiration: October 13, 2029
The two patents address distinct therapeutic-use contexts and should be interpreted according to their respective claims, prosecution history and applicable patent law.
Arterial Hypertension·Cardiac Insufficiency·Therapeutic-Use Claims·U.S. Patents
Technology IP vs. Therapeutic-Use IP
D016 is the specific recombinant hyaluronidase technology selected for pharmaceutical development.
The issued U.S. patents contain claims directed to defined therapeutic uses of hyaluronidase in cardiovascular disease.
The therapeutic-use claims are not limited in their independent claims to the specific D016 recombinant enzyme sequence. This means that the existing patent position and the D016 technology should be considered as distinct, but potentially complementary, elements of the overall development strategy.
The practical scope and enforceability of any patent remain subject to claim interpretation, prosecution history and applicable patent law.
D016 Technology·Therapeutic-Use IP·Distinct Layers·Complementary Development Strategy
Potential Patent Term Extension
Certain U.S. patents may be eligible for patent term extension under 35 U.S.C. §156, subject to future regulatory approval and satisfaction of all applicable statutory requirements.
Patent term extension is not automatic. Eligibility and the duration of any extension depend on factors including the applicable regulatory review period, the timing of regulatory approval, the status of the respective patent and the relationship between the approved product and the patent claims.
For method-of-use patents, any extended rights remain linked to the uses covered by the patent and the applicable regulatory approval.
Accordingly, potential patent term extension is considered a future regulatory and intellectual-property option and is not included in the currently stated patent expiration dates.
Current Patent Term·Potential PTE·Regulatory Approval·Statutory Requirements
Patent Scope in Context
The issued U.S. patents are method-of-use patents directed to defined cardiovascular therapeutic applications of hyaluronidase.
Their relevance therefore depends on the relationship between the patented therapeutic use, the pharmaceutical product being developed and any future regulatory approval.
The patents do not represent unrestricted protection for every potential use of hyaluronidase or D016.
Accordingly, the intellectual-property position is evaluated together with the specific claims, development indication, regulatory strategy and the broader pharmaceutical development program.
Patent protection is indication-specific and should be interpreted within the scope of the applicable claims.
Therapeutic Use·Defined Indications·Claim Scope·Development Context
IP Within the Development Strategy
Pantarhin evaluates its intellectual-property position together with scientific evidence, pharmaceutical development, regulatory strategy and potential cardiovascular development pathways.
The issued U.S. therapeutic-use patents provide an established intellectual-property layer within this broader development framework.
Their future relevance will depend on the development of D016, the indications ultimately pursued, the scope of any regulatory approvals and the applicable patent-law framework.
Intellectual property does not predetermine development success. It forms one component of the overall scientific, regulatory and pharmaceutical development strategy.
Intellectual Property·D016 Technology·Regulatory Strategy·Cardiovascular Development
Pantarhin’s issued U.S. therapeutic-use patents form part of a broader pharmaceutical development strategy centered on D016, scientific evidence and cardiovascular development. Patent relevance is evaluated in relation to the applicable claims, development context, regulatory pathway and future development decisions.
U.S. Therapeutic-Use Patents·D016 Technology·Cardiovascular Development
This website uses cookies. By continuing to use this site, you accept our use of cookies. Learn more